US imposes 100% tariff on patented pharmaceutical imports with exemptions and caveats
Consensus Summary
Donald Trump imposed a 100% tariff on patented pharmaceuticals imported into the US, targeting foreign manufacturing to boost domestic production and reduce drug prices for American consumers. The move, signed under Section 232 of the Trade Expansion Act, applies to patented drugs but exempts generics and plasma-derived therapies under specific conditions. Australia, a major exporter of pharmaceuticals to the US, faces potential tariffs on its $1.3–2 billion annual exports, though CSL, the largest biotech firm, may qualify for exemptions due to its US manufacturing operations and plasma-derived products. The Australian government has firmly rejected US pressure to alter its Pharmaceutical Benefits Scheme, which guarantees lower drug prices for Australians. Other countries like Japan, South Korea, and the EU face lower tariffs of 15%, while the UK has a 10% rate. Companies have 120 days to comply by moving production to the US or negotiating pricing deals, with smaller firms granted 180 days. The tariff reflects broader US efforts to reshoring manufacturing and address high drug costs, though it risks disrupting global supply chains and trade relationships. Australian officials, including Health Minister Mark Butler and Opposition Leader Angus Taylor, have expressed concern but pledged to advocate for exemptions and protect domestic pharmaceutical policies.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- Donald Trump signed an executive order on 2025-06-26 (Washington time) imposing a 100% tariff on patented drugs imported into the US under Section 232 of the Trade Expansion Act, unaffected by the February Supreme Court ruling on 'Liberation Day' tariffs.
- Australia exported approximately $US1.3–2.0 billion worth of pharmaceuticals to the US in 2024–2025, with CSL (Melbourne-based) accounting for the majority of these exports.
- CSL has US manufacturing facilities in Illinois (Kankakee) and North Carolina, with a $US1.5–2.2 billion expansion project underway in Illinois, set to complete by 2031.
- The tariff applies to patented drugs but not generic medicines, with exemptions for plasma-derived therapies if they meet urgent US health needs or come from countries with trade deals with the US.
- Companies can reduce tariffs to 20% by moving production to the US or to zero if they grant the US 'most favoured nation' status on drug pricing, and large companies have 120 days to comply while smaller firms have 180 days.
- Japan, South Korea, Switzerland, and the EU face a 15% tariff on pharmaceuticals, while the UK has a 10% tariff with potential for further reductions.
- Health Minister Mark Butler stated Australia would not negotiate changes to the Pharmaceutical Benefits Scheme (PBS) to accommodate US demands, calling it 'not for sale'.
- Australia and the US have a long-standing free trade agreement (since 2005) that previously exempted Australian pharmaceuticals from tariffs.
- The tariff announcement was timed to mark one year since Trump’s 'Liberation Day' tariffs (February 2025), which were later struck down by the Supreme Court.
Points of Difference
Details reported by only one source:
- The White House official explicitly stated 'Australia does not have a special pharma tariff rate' despite being a close ally.
- The tariff adjustment for steel-containing products was detailed: zero additional tariff if steel content is <15%, 25% if >15%.
- The executive order mentions 'fool the tariff process' attempts to reduce product valuation will be addressed.
- The tariff applies to products derived from blood plasma in certain circumstances, with a focus on 'urgent US health need'.
- The tariff was described as part of a broader effort to 're-shore production in the US' and reduce reliance on foreign manufacturing.
- The Guardian emphasized Australia's annual pharmaceutical exports to the US are worth about $2 billion, with CSL's plasma therapies expected to receive exemptions.
- The article highlighted that Trump's plan aims to force manufacturers to agree to drug-pricing deals or commit to US manufacturing, citing affordability concerns for American consumers.
- The Guardian quoted Communications Minister Anika Wells stating the Australian PBS is 'not for sale' and 'world leading'.
- The article noted that the tariff announcement was timed to address US consumer frustration over higher drug prices compared to other countries.
- The ABC reported Trump previously stated the tariff could be as high as 200%, but it was ultimately set at 100%.
- The ABC mentioned the tariff is being implemented under Section 232 of the Trade Expansion Act, which protects national security and is unaffected by the Supreme Court ruling.
- The ABC included a direct quote from a senior administration official: 'While we research and we develop them, and we're the innovators and we are the patent holders, we've allowed other countries to make the drugs — and therefore were beholden to these other countries.'
- The ABC noted that 17 deals have already been negotiated to move hundreds of billions of dollars worth of manufacturing to the US.
- The ABC reported the tariff would apply to patented drugs but not generic medicines, with a focus on re-shoring production.
- SBS included a direct quote from Health Minister Mark Butler calling the decision 'deeply disappointing and deeply concerning'.
- SBS did not provide specific financial figures for Australian pharmaceutical exports to the US, unlike other sources.
- The SMH repeated details from THEAGE regarding the tariff's application to plasma-derived therapies and the exemption process for CSL.
- The SMH included a quote from Trade Minister Don Farrell's spokesman about the government's disappointment and intent to argue for tariff removal.
- NEWSCOMAU reported that Medicines Australia warned of a slowdown in new medicines coming to Australia due to 'most favoured nation' rules, with international headquarters delaying launches.
- The article included a quote from Prime Minister Marles (not mentioned in other sources) about the 20-year free trade agreement with the US.
- NEWSCOMAU stated the tariff kicks in on July 31, 2025, with details of the executive order showing companies like AstraZeneca have already struck specific deals with the White House.
Where the reporting differs
Details that conflict, or appear in only some outlets:
- The Guardian and ABC both report Australia exports ~$2 billion in pharmaceuticals to the US, but THEAGE and SMH cite ~$1.3–1.5 billion, with COMTRADE data referenced in ABC and NEWSCOMAU.
- The Guardian and NEWSCOMAU state the tariff applies to patented drugs but not generic medicines, but THEAGE does not explicitly mention generics being exempt.
- The ABC reports Trump previously stated the tariff could be as high as 200%, but THEAGE and SMH do not mention this 200% figure.
- NEWSCOMAU reports the tariff kicks in on July 31, 2025, while other sources do not specify an exact date but mention a 120-day window for large companies to comply.
- The Guardian and NEWSCOMAU highlight the impact of 'most favoured nation' rules on new medicine launches in Australia, but THEAGE and ABC do not emphasize this aspect.
Source Articles
What Trump's 100 per cent pharmaceutical tariff means for Australia
Australia exported nearly two billion dollars worth of pharmaceuticals to the US last year.
Australia says it won’t raise drug prices after Trump’s 100% tariff on pharmaceuticals imported into US
Health minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medications Get our breaking news email , free app or daily news podcast Australia will not cave in to pressure from pharmaceutical giants and the Trump administration by removing consumer price protections on common medications, the health minister, Mark Butler says. Donald Trump imposed a new 100% tariff on branded pharmaceuticals imported into the US overnight, Austra
Trump slaps huge tariff on medicines
US President Donald Trump has followed through on another tariff threat, putting a 100 per cent levy on a major Australian export.
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances.
Breaking: Trump puts 100pc tariff on some pharmaceuticals
The US president's latest order shows he remains committed to his aggressive tariff regime despite February's Supreme Court ruling that invalidated his centrepiece "liberation day" tariffs.
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances.
More Business stories
Jetstar introduces new carry-on baggage fees and size restrictions from 2027
ABC retracts Four Corners episodes by sacked reporter Mahmood Fazal over accuracy concerns
NSW government announces partial Sydney toll road price reductions and reforms
CFMEU corruption inquiry implicates Mick Gatto in labour hire schemes and tax evasion
Australia considers first new oil refinery in decades amid fuel security crisis
Melbourne businessman convicted of rape after three-week trial
Latest cross-verified stories
Sydney Swans players linked to sexual assault allegations and club sanctions
Australia vs Bangladesh Test series in 2026, featuring historic upsets and batting struggles
Ukraine targets Wildberries warehouses and Russian infrastructure with drone strikes amid escalating war
Meta trial over social media addiction in children begins in California
Prince Harry and others ordered to pay legal costs to Daily Mail publisher after losing privacy lawsuit
Mass bird deaths linked to H5 bird flu in Australia’s southern states
Browse all stories from April 2026 in the archive.